$CYCN News

Cyclerion Therapeutics Announces September 4 Record Date For Contingent Value Rights Distribution To Common And Series A Preferred Holders In Connection With Planned Korsana Biosciences Merger

Cyclerion Therapeutics Q1 EPS $(0.76) Down From $(0.56) YoY

Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline

Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

Cyclerion Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement with Korsana Biosciences.

Cyclerion Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement with Korsana Biosciences.

Cyclerion And Korsana Biosciences Announce All-Stock Merger With $380M Private Financing To Advance Alzheimer's Drug KRSA-028 Through 2029

CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Watching Cyclerion Therapeutics; Zacks Small-Cap Research Gives Stock $8.00 Price Valuation

CYCN: Engineering a Reset; Initiating Coverage of Cyclerion Therapeutics…

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression - Slideshow

BC-Most Active Stocks

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion Therapeutics shares are trading higher after the company announced it is expanding strategic collaboration with Medsteer to advance closed-loop anesthetic platform CYC-126.

Cyclerion Therapeutics Collaborates With Medsteer To Integrate Medsteer's Technology Into Cyclerion's CYC-126 Program

Cyclerion Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "sGC STIMULATORS (USEFUL FOR TREATING, PREVENTING OR MANAGING VARIOUS DISORDERS)".